Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers

Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers Publisher

Zandi M¹ ; Shafaati M² ; Shenagari M³ ; Naziri H³

Source: Heliyon Published:2023

Abstract

Macrophages are essential mediators of innate immunity. Non-self-cells resist phagocytosis through the expression of the checkpoint molecule CD47. CD47, as the integrin-associated protein, is overexpressed on tumor and SARS-CoV-2-infected cells as a potential surface biomarker for immune surveillance evasion. CD47-signal-regulating protein alpha (SIRPα) interaction is a promising innate immunotarget. Previous findings based on monoclonal antibodies (mAbs) or fusion proteins that block CD47 or SIRPα have been developed in cancer research. While CD47 efficacy in infectious diseases, especially severe COVID-19 studies, is lacking, focus on macrophage-mediated immunotherapy that increases “eat me” signals in combination therapy with mAbs is optimistic. This integrin-related protein can be as a potential target to therapy for COVID-19. Here, we concentrate on the role of the CD47 signaling pathway as a novel therapeutic strategy for COVID-19-associated cancer treatment. © 2023 The Author(s)

Related Docs

View other Related Docs

1. Targeting Macrophage-Mediated Tumor Cell Phagocytosis: An Overview of Phagocytosis Checkpoints Blockade, Nanomedicine Intervention, and Engineered Car-Macrophage Therapy, International Immunopharmacology (2022)

2. Don't Eat Me/Eat Me Signals As a Novel Strategy in Cancer Immunotherapy, Heliyon (2023)

3. The Complex Role of Macrophages in Pancreatic Cancer Tumor Microenvironment: A Review on Cancer Progression and Potential Therapeutic Targets, Discover Oncology (2024)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (4)

Hamid Reza Mirzaei (1)

Style	Citing Format
MLA	Zandi M, et al.. "Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers." Heliyon, vol. 9, no. 7, 2023, pp. -.
APA	Zandi M, Shafaati M, Shenagari M, Naziri H (2023). Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers. Heliyon, 9(7), -.
Chicago	Zandi M, Shafaati M, Shenagari M, Naziri H. "Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers." Heliyon 9, no. 7 (2023): -.
Harvard	Zandi M et al. (2023) 'Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers', Heliyon, 9(7), pp. -.
Vancouver	Zandi M, Shafaati M, Shenagari M, Naziri H. Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers. Heliyon. 2023;9(7):-.
BibTex	@article{ author = {Zandi M and Shafaati M and Shenagari M and Naziri H}, title = {Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers}, journal = {Heliyon}, volume = {9}, number = {7}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Zandi M AU - Shafaati M AU - Shenagari M AU - Naziri H TI - Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers JO - Heliyon VL - 9 IS - 7 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Abstract